A bispecific antibody inhibits FGFR3 dimerization and is highly effective in FGFR3-driven tumor models

被引：0
|
作者：
Yang, Yan
Avvaru, Naga Suhasini
Jiang, Zaoli
Liu, Nina
Rosconi, Michael
Zhang, Bojie
Li, Yinyin
Ullman, Erica
Lin, John Chia-Yang
Shen, Yang
Daly, Christopher
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2023年 / 22卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-23-B129
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B129
引用
收藏
页数：2
相关论文
共 50 条
  • [21] FGFR3 has tumor suppressor properties in cells with epithelial phenotype
    Lafitte, Marie
    Moranvillier, Isabelle
    Garcia, Stephane
    Peuchant, Evelyne
    Iovanna, Juan
    Rousseau, Benoit
    Dubus, Pierre
    Guyonnet-Duperat, Veronique
    Belleannee, Genevieve
    Ramos, Jeanne
    Bedel, Aurelie
    de Verneuil, Hubert
    Moreau-Gaudry, Francois
    Dabernat, Sandrine
    MOLECULAR CANCER, 2013, 12
  • [22] Measurements of FGFR3 dimerization in the plasma membrane using Forster resonance energy transfer
    Li, Edwin
    Chen, Fenhao
    Merzlyakov, Mikhail
    Placone, Jesse
    Hristova, Kalina
    BIOPHYSICAL JOURNAL, 2007, : 558A - 558A
  • [23] FGFR3 has tumor suppressor properties in cells with epithelial phenotype
    Marie Lafitte
    Isabelle Moranvillier
    Stéphane Garcia
    Evelyne Peuchant
    Juan Iovanna
    Benoit Rousseau
    Pierre Dubus
    Véronique Guyonnet-Dupérat
    Geneviève Belleannée
    Jeanne Ramos
    Aurélie Bedel
    Hubert de Verneuil
    François Moreau-Gaudry
    Sandrine Dabernat
    Molecular Cancer, 12
  • [24] Overexpression of miR-100 inhibits growth of osteosarcoma through FGFR3
    Bi, Yunlong
    Jing, Yu
    Cao, Yang
    TUMOR BIOLOGY, 2015, 36 (11) : 8405 - 8411
  • [25] Combination synergy of JAK inhibitor, BVB808, and FGFR inhibitor, BGJ398, in an FGFR3-driven multiple myeloma model
    Pinzon-Ortiz, Maria
    Tan, Lujian
    Yao, Yao
    Schlegel, Robert
    Radimerski, Thomas
    Cao, Z. Alexander
    CANCER RESEARCH, 2012, 72
  • [26] A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia
    Jin, Min
    Yu, Ying
    Qi, Huabing
    Xie, Yangli
    Su, Nan
    Wang, Xiaofeng
    Tan, Qiaoyan
    Luo, Fengtao
    Zhu, Ying
    Wang, Quan
    Du, Xiaolan
    Xian, Cory J.
    Liu, Peng
    Huang, Haiyang
    Shen, Yue
    Deng, Chu-Xia
    Chen, Di
    Chen, Lin
    HUMAN MOLECULAR GENETICS, 2012, 21 (26) : 5443 - 5455
  • [27] Mechanistic studies of AV370, a potent FGFR3 antagonistic antibody
    Bai, Ailin
    Winston, William
    Meetze, Kristan
    Kollipara, Sriram
    Woo, Jin-Kyeung
    Nhi Vo
    Kosmatka, Monica
    Breault, Lyne
    Weiler, Solly
    Kabbarah, Omar
    Boudrow, Andrea
    Connolly, Kelly
    DiPrima, Michael
    Tissire, Hamid
    Jiang, Jinwei
    Gyuris, Jeno
    Weng, Zhigang
    CANCER RESEARCH, 2009, 69
  • [28] Effect of pathogenic cysteine mutations on FGFR3 transmembrane domain dimerization in detergents and lipid bilayers
    You, Min
    Spangler, Jamie
    Li, Edwin
    Han, Xue
    Ghosh, Pijush
    Hristova, Kalina
    BIOCHEMISTRY, 2007, 46 (39) : 11039 - 11046
  • [29] Effect of the achondroplasia mutation on FGFR3 dimerization and FGFR3 structural response to fgf1 and fgf2: A quantitative FRET study in osmotically derived plasma membrane vesicles
    Sarabipour, Sarvenaz
    Hristova, Kalina
    BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2016, 1858 (07): : 1436 - 1442
  • [30] The Hsp90 inhibitor ganetespib promotes the degradation of FGFR3 in bladder cancer models and induces regression in tumors harboring oncogenic FGFR3 fusions.
    Acquaviva, Jaime L.
    Zhang, Chaohua
    He, Suqin
    Jimenez, John-Paul
    Nagai, Masa
    Sang, Jim
    Sequeira, Manuel
    Smith, Donald L.
    Knowles, Margaret A.
    Proia, David A.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
12345